Matinas BioPharma Holdings, Inc. Sustainability Profile
Matinas BioPharma Holdings, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for serious diseases. Founded in 2015, Matinas has made significant strides in the biotechnology sector, particularly in the areas of lipid-based drug delivery systems and oral formulations. The company’s flagship product, MAT2203, is a unique oral formulation of amphotericin B, designed to treat fungal infections with improved safety and efficacy. Matinas BioPharma's commitment to advancing drug delivery technologies positions it as a notable player in the biopharma industry, with a strong emphasis on enhancing patient outcomes. With a robust pipeline and strategic partnerships, Matinas continues to solidify its market position and drive innovation in the healthcare landscape.
DitchCarbon Score
How does Matinas BioPharma Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Matinas BioPharma Holdings, Inc.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Matinas BioPharma Holdings, Inc.'s reported carbon emissions
In 2022, Matinas BioPharma Holdings, Inc. reported total carbon emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. This data reflects the company's operational footprint and highlights its commitment to transparency in emissions reporting. In 2021, the company reported significantly higher Scope 1 emissions of about 533,000,000 kg CO2e, indicating a substantial reduction in emissions in the following year. However, there are currently no reported Scope 3 emissions, nor are there any disclosed reduction targets or climate pledges, suggesting that Matinas BioPharma has yet to establish formal commitments to further reduce its carbon footprint. The absence of cascaded emissions data from a parent or related organization indicates that Matinas BioPharma's emissions reporting is independent. As the company continues to evolve, it may consider setting specific reduction targets to align with industry standards and enhance its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Matinas BioPharma Holdings, Inc.'s Industry?
How Carbon Intensive is Matinas BioPharma Holdings, Inc.'s Location?
Matinas BioPharma Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Matinas BioPharma Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
